During the recent session, BioXcel Therapeutics Inc (NASDAQ:BTAI)’s traded shares were 0.5 million, with the beta value of the company hitting 0.58. At the last check today, the stock’s price was $2.55, reflecting an intraday loss of -6.59% or -$0.18. The 52-week high for the BTAI share is $52.80, that puts it down -1970.59 from that peak though still a striking 32.55% gain since the share price plummeted to a 52-week low of $1.72. The company’s market capitalization is $8.39M, and the average trade volume was 4.58 million shares over the past three months.
BioXcel Therapeutics Inc (BTAI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.25. BTAI has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 7 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -5.14.
BioXcel Therapeutics Inc (NASDAQ:BTAI) trade information
BioXcel Therapeutics Inc (BTAI) registered a -6.59% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -6.59% in intraday trading to $2.55, hitting a weekly high. The stock’s 5-day price performance is 47.40%, and it has moved by -44.08% in 30 days. Based on these gigs, the overall price performance for the year is -94.89%.
The consensus price target of analysts on Wall Street is $1, which implies a decrease of -155.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1 and $1 respectively. As a result, BTAI is trading at a premium of 60.78% off the target high and 60.78% off the low.
BioXcel Therapeutics Inc (BTAI) estimates and forecasts
In the rating firms’ projections, revenue will increase 106.09% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 718.26k as predicted by 5 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to 350k by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 376k and 582k respectively. In this case, analysts expect current quarter sales to grow by 91.03% and then drop by -39.86% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -35.97%. While earnings are projected to return 74.52% in 2025, the next five years will return 50.29% per annum.
BTAI Dividends
BioXcel Therapeutics Inc is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
BioXcel Therapeutics Inc (NASDAQ:BTAI)’s Major holders
The next largest institutional holding, with 0.44 million shares, is of BLACKROCK INC.’s that is approximately 1.4276% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $0.56 million.
Also, the Mutual Funds coming in first place with the largest holdings of BioXcel Therapeutics Inc (BTAI) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 55.39 shares. This amounts to just over 0.11 percent of the company’s overall shares, with a $0.14 million market value. The same data shows that the other fund manager holds slightly less at 18.33, or about 0.04% of the stock, which is worth about $47002.0.
